Wockhardt stock up 10% as Zaynich achieves 96.8% efficacy in Phase III
Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with ...
EUR/JPY Price Forecast: Key downside target emerges near 160.00
The EUR/JPY cross gains momentum to around 160.75, snapping the two-day losing streak during the early European session on ...
Top 3 Price Prediction Bitcoin, Ethereum, Ripple: BTC, ETH and XRP recovery could be short-lived
Bitcoin (BTC) price hovers around $104,000 on Friday after bouncing off from its 50-day Exponential Moving Average (EMA) of ...
GlobalData on MSN15h
EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Business Wire1h
PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy
PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative ...
Japanese Yen and Aussie Dollar News: BoJ vs. Fed Rate Path Battle Heats Up
Japan’s retail sales and job data fuel BoJ rate hike bets, pressuring USD/JPY. Fed’s inflation stance also in focus. Will USD ...
Ozempic-Like Drugs May Hold Risks For Surgical Patients, Officials Say
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.
Taiwan News19h
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™
To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1‑800-FDA-1088 or www.fda.gov/medwatch.